HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan

manilatimes.net · 2026-11-02

- Follows US FDA new drug application submission in September 2026, marking important global regulatory progress -

TickrTrends take: HUTCHMED's advancement of ORPATHYS in combination with TAGRISSO represents a potential expansion of AstraZeneca's oncology portfolio in a therapeutically significant indication, as TAGRISSO is a key revenue driver for the company's lung cancer franchise. Given TickrTrends' current undervalued assessment, investors focused on valuation should monitor whether regulatory approvals in Europe and Japan could meaningfully contribute to future revenue streams and support the company's growth trajectory in precision medicine. The acceptance of these filings for review indicates near-term catalysts that could validate the commercial potential of this combination therapy across major markets.

Read the full story at manilatimes.net →